Denali Therapeutics Inc. Stock News

Denali Therapeutics Inc (NASDAQ:DNLI) was the recipient of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 8,910,000 shares, a decrea

BIONDVAX PHARMA/S (NASDAQ:BVXV) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their a

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

Goldman Sachs Group Inc. lowered its position in Denali Therapeutics Inc (NASDAQ:DNLI) by 3.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities &

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index wa

In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Denali Therapeutics (DNLI), with a price target of $28.00. The

In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Denali Therapeutics ( DNLI – Research Report ), with a price target of $28.00 . The company’s shares clo

Bank of New York Mellon Corp reduced its position in shares of Denali Therapeutics Inc (NASDAQ:DNLI) by 0.8% in the fourth quarter, according to the company in its most recent disclosure with the Secu

Sean McCarthy, president and CEO of CytomX Therapeutics Inc.

AQR Capital Management LLC trimmed its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 28.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commissi

We note that the Denali Therapeutics Inc. (NASDAQ:DNLI) Co-Founder, Ryan Watts, recently sold US$94k worth of stock...

Denali Therapeutics Inc (NASDAQ:DNLI) CEO Ryan J. Watts sold 4,807 shares of the company’s stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $19